<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Publishing DTD v1.3 20210610//EN" "JATS-journalpublishing1-3.dtd">
<article article-type="review-article" dtd-version="1.3" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xml:lang="en"><front><journal-meta><journal-id journal-id-type="publisher-id">nnp</journal-id><journal-title-group><journal-title xml:lang="en">Neurology, Neuropsychiatry, Psychosomatics</journal-title><trans-title-group xml:lang="ru"><trans-title>Неврология, нейропсихиатрия, психосоматика</trans-title></trans-title-group></journal-title-group><issn pub-type="ppub">2074-2711</issn><issn pub-type="epub">2310-1342</issn><publisher><publisher-name>"IMA-Press", LLC</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="doi">10.14412/2074-2711-2025-3-98-103</article-id><article-id custom-type="elpub" pub-id-type="custom">nnp-2636</article-id><article-categories><subj-group subj-group-type="heading"><subject>Research Article</subject></subj-group><subj-group subj-group-type="section-heading" xml:lang="en"><subject>REVIEWS</subject></subj-group><subj-group subj-group-type="section-heading" xml:lang="ru"><subject>ОБЗОРЫ</subject></subj-group></article-categories><title-group><article-title>Parkinson's disease and migraine</article-title><trans-title-group xml:lang="ru"><trans-title>Болезнь Паркинсона и мигрень</trans-title></trans-title-group></title-group><contrib-group><contrib contrib-type="author" corresp="yes"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0001-8718-7266</contrib-id><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Залялова</surname><given-names>З. А.</given-names></name><name name-style="western" xml:lang="en"><surname>Zalyalova</surname><given-names>Z. A.</given-names></name></name-alternatives><bio xml:lang="ru"><p>Зулейха Абдуллазяновна Залялова</p><p>420012, Казань, ул. Бутлерова, 49</p><p>420061, Казань, ул. Исаева 5; 3Россия, 117997</p></bio><bio xml:lang="en"><p>Zuleikha Abdullazyanovna Zalyalova</p><p>49, Butlerova St., Kazan 420012</p><p>5, Isaeva St., Kazan 420061</p></bio><email xlink:type="simple">z.zalyalova@gmail.com</email><xref ref-type="aff" rid="aff-1"/></contrib><contrib contrib-type="author" corresp="yes"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0001-5805-486X</contrib-id><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Катунина</surname><given-names>Е. А.</given-names></name><name name-style="western" xml:lang="en"><surname>Katunina</surname><given-names>E. A.</given-names></name></name-alternatives><bio xml:lang="ru"><p>117997, Москва, ул. Островитянова, 1</p><p>117513, Москва, ул. Островитянова, 1, стр. 10</p></bio><bio xml:lang="en"><p>1, Ostrovityanova St., Moscow 117997</p><p>1, Ostrovityanova St., Build. 10, Moscow 117997</p></bio><xref ref-type="aff" rid="aff-2"/></contrib><contrib contrib-type="author" corresp="yes"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0003-3355-6278</contrib-id><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Похабов</surname><given-names>Д. В.</given-names></name><name name-style="western" xml:lang="en"><surname>Pokhabov</surname><given-names>D. V.</given-names></name></name-alternatives><bio xml:lang="ru"><p>660022, Красноярск, ул. Партизана Железняка, 1</p><p>660037, Красноярск, ул. Коломенская, 26</p></bio><bio xml:lang="en"><p>1, Partizana Zheleznyayka St., Krasnoyarsk 660022</p><p>26, Kolomenskaya St., Krasnoyarsk 660037</p></bio><xref ref-type="aff" rid="aff-3"/></contrib></contrib-group><aff-alternatives id="aff-1"><aff xml:lang="ru"><institution>ФГБОУ ВО «Казанский государственный медицинский университет» Минздрава России; Консультативно-диагностический центр экстрапирамидной патологии и ботулинотерапии Республики Татарстан</institution><country>Россия</country></aff><aff xml:lang="en"><institution>Kazan State Medical University, Ministry of Health of Russia; Consultative and Diagnostic Center for Extrapyramidal Disorders and Botulinum Therapy</institution><country>Russian Federation</country></aff></aff-alternatives><aff-alternatives id="aff-2"><aff xml:lang="ru"><institution>3кафедра неврологии, нейрохирургии и медицинской генетики ФГАОУ ВО «Российский национальный исследовательский медицинский университет им. Н.И. Пирогова»; отдел нейродегенеративных заболеваний ФГБУ «Федеральный центр мозга и нейротехнологий» ФМБА России</institution><country>Россия</country></aff><aff xml:lang="en"><institution>Department of Neurology, Neurosurgery and Medical Genetics, &#13;
N.I. Pirogov Russian National Research Medical University, Ministry of Health of Russia; Department of Neurodegenerative Diseases, Federal Center for Brain and Neurotechnologies, FMBA of Russia</institution><country>Russian Federation</country></aff></aff-alternatives><aff-alternatives id="aff-3"><aff xml:lang="ru"><institution>кафедра нервных болезней с курсом ПО ФГБОУ ВО «Красноярский государственный медицинский университет им. проф. В.Ф. Войно-Ясенецкого» Минздрава России; Центр инновационной неврологии, экстрапирамидных заболеваний и ботулинотерапии ФГБУЗ «Федеральный Сибирский научно-клинический центр» ФМБА России</institution><country>Россия</country></aff><aff xml:lang="en"><institution>Department of Nervous Diseases, Prof. V.F. Voino-Yasenetsky Krasnoyarsk State Medical University, Ministry of Health of Russia; Center for Innovative Neurology, Extrapyramidal Diseases and Botulinum Therapy, Federal Siberian Research Clinical Center</institution><country>Russian Federation</country></aff></aff-alternatives><pub-date pub-type="collection"><year>2025</year></pub-date><pub-date pub-type="epub"><day>24</day><month>06</month><year>2025</year></pub-date><volume>17</volume><issue>3</issue><fpage>98</fpage><lpage>103</lpage><permissions><copyright-statement>Copyright &amp;#x00A9; Zalyalova Z.A., Katunina E.A., Pokhabov D.V., 2025</copyright-statement><copyright-year>2025</copyright-year><copyright-holder xml:lang="ru">Залялова З.А., Катунина Е.А., Похабов Д.В.</copyright-holder><copyright-holder xml:lang="en">Zalyalova Z.A., Katunina E.A., Pokhabov D.V.</copyright-holder><license xml:lang="ru" license-type="creative-commons-attribution" xlink:href="https://creativecommons.org/licenses/by/4.0/" xlink:type="simple"><license-p>Данная работа распространяется под лицензией Creative Commons Attribution 4.0.</license-p></license><license xml:lang="en" license-type="creative-commons-attribution" xlink:href="https://creativecommons.org/licenses/by/4.0/" xlink:type="simple"><license-p>This work is licensed under a Creative Commons Attribution 4.0 License.</license-p></license></permissions><self-uri xlink:href="https://nnp.ima-press.net/nnp/article/view/2636">https://nnp.ima-press.net/nnp/article/view/2636</self-uri><abstract><p>Parkinson's disease (PD) is one of the most common neurodegenerative disorders. Migraine is the most prevalent neurological condition among adults. It has been established that migraine often precedes the development of PD, and with the onset of motor symptoms and/or the initiation of specific therapy, both the frequency and severity of migraine attacks significantly decrease. It is likely that the two conditions share common functional and biochemical characteristics. If brainstem nuclei disintegration and dopaminergic neurotransmission dysregulation are involved in the pathogenesis of migraine, then studying patients with migraine who go on to develop PD may provide important insights into the role of dopamine and/or dopaminergic brainstem regions in the pathogenesis of both migraine and PD. This review focuses on studies addressing epidemiology, the role of dopaminergic system genes in migraine development, mechanisms linking the two diseases, and the impact of pharmacological therapy.</p></abstract><trans-abstract xml:lang="ru"><p>Болезнь Паркинсона (БП) – одно из наиболее частых нейродегенеративных заболеваний. Мигрень – наиболее распространенное неврологическое заболевание взрослых. Установлено, что мигрень часто предшествует развитию БП, а с дебютом моторных проявлений и/или началом специфической терапии частота и выраженность приступов мигрени значительно снижаются. Вероятно, оба заболевания имеют общие функциональные и биохимические черты. Если дезинтеграция ядер ствола мозга и дизрегуляция дофаминергической нейропередачи имеют отношение к патогенезу мигрени, то исследование пациентов с мигренью, у которых развивается БП, может предоставить важную информацию о роли дофамина и/или дофаминергических областей ствола мозга в патогенезе как мигрени, так и БП. Обзор посвящен исследованиям эпидемиологии, роли генов дофаминергической системы в развитии мигрени, механизмам взаимосвязи обоих заболеваний и влиянию медикаментозной терапии.</p></trans-abstract><kwd-group xml:lang="ru"><kwd>болезнь Паркинсона</kwd><kwd>мигрень</kwd><kwd>дофамин</kwd><kwd>серотонин</kwd><kwd>агонисты дофаминовых рецепторов</kwd><kwd>пирибедил</kwd><kwd>леводопа</kwd></kwd-group><kwd-group xml:lang="en"><kwd>Parkinson's disease</kwd><kwd>migraine</kwd><kwd>dopamine</kwd><kwd>serotonin</kwd><kwd>dopamine receptor agonists</kwd><kwd>piribedil</kwd><kwd>levodopa</kwd></kwd-group><funding-group><funding-statement xml:lang="ru">Статья спонсируется компанией «Сервье».</funding-statement><funding-statement xml:lang="en">The article is sponsored by Servier.</funding-statement></funding-group></article-meta></front><back><ref-list><title>References</title><ref id="cit1"><label>1</label><citation-alternatives><mixed-citation xml:lang="ru">Азимова ЮЭ, Амелин АВ, Алферова ВВ и др. Клинические рекомендации «Мигрень». Журнал неврологии и психиатрии им. С.С. Корсакова. 2022;122(1-3):4-36. doi: 10.17116/jnevro20221220134</mixed-citation><mixed-citation xml:lang="en">Azimova YuE, Amelin AV, Alferova VV, et al. Clinical guidelines “Migraine". Zhurnal nevrologiii psikhiatrii imeni S.S. Korsakova = S.S. Korsakov Journal of Neurology and Psychiatry. 2022;122(1-3):4-36. doi: 10.17116/jnevro20221220134 (In Russ.)].</mixed-citation></citation-alternatives></ref><ref id="cit2"><label>2</label><citation-alternatives><mixed-citation xml:lang="ru">Ali MD, Gayasuddin Qur F, Alam MS, et al. Global Epidemiology, Clinical Features, Diagnosis and Current Therapeutic Novelties in Migraine Therapy and their Prevention: A Narrative Review. Curr Pharm Des. 2023;29(41):3295-311. doi: 10.2174/0113816128266227231205114320</mixed-citation><mixed-citation xml:lang="en">Ali MD, Gayasuddin Qur F, Alam MS, et al. Global Epidemiology, Clinical Features, Diagnosis and Current Therapeutic Novelties in Migraine Therapy and their Prevention: A Narrative Review. Curr Pharm Des. 2023;29(41):3295-311. doi: 10.2174/0113816128266227231205114320</mixed-citation></citation-alternatives></ref><ref id="cit3"><label>3</label><citation-alternatives><mixed-citation xml:lang="ru">Шток ВН, Иванова-Смоленская ИА, Левина ОС, редакторы. Экстрапирамидные расстройства. Руководство по диагностике и лечению. Москва: МЕДпресс-информ, 2002. 608 с.</mixed-citation><mixed-citation xml:lang="en">Shtok VN, Ivanova-Smolenskaya IA, Levin OS, editors. Extrapyramidal disorders. Guide to diagnostics and treatment. Moscow: MEDpress-inform; 2002. 608 p. (In Russ.)].</mixed-citation></citation-alternatives></ref><ref id="cit4"><label>4</label><citation-alternatives><mixed-citation xml:lang="ru">Болезнь Паркинсона, вторичный паркинсонизм и другие заболевания, проявляющиеся синдромом паркинсонизма. Клинические рекомендации. 2021. Доступно по ссылке: https://cr.minzdrav.gov.ru/recomend/716_1 [Parkinson’s disease, secondary parkinsonism and other diseases that manifest as parkinsonism syndrome. Clinical Recommendations. 2021. Available at: https://cr.minzdrav.gov.ru/recomend/716_1 (In Russ.)].</mixed-citation><mixed-citation xml:lang="en">Parkinson’s disease, secondary parkinsonism and other diseases that manifest as parkinsonism syndrome. Clinical Recommendations. 2021. Available at: https://cr.minzdrav.gov.ru/recomend/716_1 (In Russ.)].</mixed-citation></citation-alternatives></ref><ref id="cit5"><label>5</label><citation-alternatives><mixed-citation xml:lang="ru">Tysnes O-B, Storstein A. Epidemiology of Parkinson's disease. J Neural Transm (Vienna). 2017 Aug;124(8):901-5. doi: 10.1007/s00702-017-1686-y. Epub 2017 Feb 1.</mixed-citation><mixed-citation xml:lang="en">Tysnes O-B, Storstein A. Epidemiology of Parkinson's disease. J Neural Transm (Vienna). 2017 Aug;124(8):901-5. doi: 10.1007/s00702-017-1686-y. Epub 2017 Feb 1.</mixed-citation></citation-alternatives></ref><ref id="cit6"><label>6</label><citation-alternatives><mixed-citation xml:lang="ru">Ashina S, Bentivegna E, Martelletti P, Eikermann-Haerter K. Structural and Functional Brain Changes in Migraine. Pain Ther. 2021 Jun;10(1):211-23. doi: 10.1007/s40122-021-00240-5. Epub 2021 Feb 16.</mixed-citation><mixed-citation xml:lang="en">Ashina S, Bentivegna E, Martelletti P, Eikermann-Haerter K. Structural and Functional Brain Changes in Migraine. Pain Ther. 2021 Jun;10(1):211-23. doi: 10.1007/s40122-021-00240-5. Epub 2021 Feb 16.</mixed-citation></citation-alternatives></ref><ref id="cit7"><label>7</label><citation-alternatives><mixed-citation xml:lang="ru">Barbanti P, Fofi L, Aurilia C, Egeo G. Dopaminergic symptoms in migraine. Neurol Sci. 2013 May;34 Suppl 1:S67-70. doi: 10.1007/s10072-013-1415-8</mixed-citation><mixed-citation xml:lang="en">Barbanti P, Fofi L, Aurilia C, Egeo G. Dopaminergic symptoms in migraine. Neurol Sci. 2013 May;34 Suppl 1:S67-70. doi: 10.1007/s10072-013-1415-8</mixed-citation></citation-alternatives></ref><ref id="cit8"><label>8</label><citation-alternatives><mixed-citation xml:lang="ru">Ha WS, Kim J, Hwang HW, et al. The association between migraine and Parkinson's disease: a nationwide cohort study. Epidemiol Health. 2024;46:e2024010. doi: 10.4178/epih.e2024010. Epub 2023 Dec 18.</mixed-citation><mixed-citation xml:lang="en">Ha WS, Kim J, Hwang HW, et al. The association between migraine and Parkinson's disease: a nationwide cohort study. Epidemiol Health. 2024;46:e2024010. doi: 10.4178/epih.e2024010. Epub 2023 Dec 18.</mixed-citation></citation-alternatives></ref><ref id="cit9"><label>9</label><citation-alternatives><mixed-citation xml:lang="ru">Todt U, Netzer C, Toliat M, et al. New genetic evidence for involvement of the dopamine system in migraine with aura. Hum Genet. 2009 Apr;125(3):265-79. doi: 10.1007/s00439-009-0623-z. Epub 2009 Jan 17.</mixed-citation><mixed-citation xml:lang="en">Todt U, Netzer C, Toliat M, et al. New genetic evidence for involvement of the dopamine system in migraine with aura. Hum Genet. 2009 Apr;125(3):265-79. doi: 10.1007/s00439-009-0623-z. Epub 2009 Jan 17.</mixed-citation></citation-alternatives></ref><ref id="cit10"><label>10</label><citation-alternatives><mixed-citation xml:lang="ru">Fernandez F, Lea RA, Colson NJ, et al.Association between a 19 bp deletion polymorphism at the dopamine beta-hydroxylase (DBH) locus and migraine with aura. J Neurol Sci. 2006 Dec 21;251(1-2):118-23. doi: 10.1016/j.jns.2006.09.013. Epub 2006 Nov 7.</mixed-citation><mixed-citation xml:lang="en">Fernandez F, Lea RA, Colson NJ, et al.Association between a 19 bp deletion polymorphism at the dopamine beta-hydroxylase (DBH) locus and migraine with aura. J Neurol Sci. 2006 Dec 21;251(1-2):118-23. doi: 10.1016/j.jns.2006.09.013. Epub 2006 Nov 7.</mixed-citation></citation-alternatives></ref><ref id="cit11"><label>11</label><citation-alternatives><mixed-citation xml:lang="ru">Сергеев АВ, Гузий ЕА, Ковальчук НАи др. Роль генов дофаминергической системы в развитии хронической мигрени и лекарственно-индуцированной головной боли. Российский журнал боли. 2024;22(4):24-9. doi: 10.17116/pain20242204124</mixed-citation><mixed-citation xml:lang="en">Sergeev AV, Guziy EA, Kovalchuk NA, et al. The role of dopaminergic system genes in the development of chronic migraine and drug-induced headache. Rossiyskiy zhurnal boli = Russian Journal of Pain. 2024;22(4):24-9. doi: 10.17116/pain20242204124 (In Russ.)].</mixed-citation></citation-alternatives></ref><ref id="cit12"><label>12</label><citation-alternatives><mixed-citation xml:lang="ru">Nunes JC, Costa Bergamaschi EN, Freitas FC, et al. Prevalence of headache in patients with Parkinson's disease and its association with the side of motor symptom onset. Neurol Sci. 2014 Apr;35(4):595-600. doi: 10.1007/s10072-013-1571-x. Epub 2013 Nov 7.</mixed-citation><mixed-citation xml:lang="en">Nunes JC, Costa Bergamaschi EN, Freitas FC, et al. Prevalence of headache in patients with Parkinson's disease and its association with the side of motor symptom onset. Neurol Sci. 2014 Apr;35(4):595-600. doi: 10.1007/s10072-013-1571-x. Epub 2013 Nov 7.</mixed-citation></citation-alternatives></ref><ref id="cit13"><label>13</label><citation-alternatives><mixed-citation xml:lang="ru">Suzuki K, Okuma Y, Uchiyama T, et al. The prevalence, course and clinical correlates of migraine in Parkinson's disease: A multicentre case-controlled study. Cephalalgia. 2018;38:1535-44. doi: 10.1177/0333102417739302</mixed-citation><mixed-citation xml:lang="en">Suzuki K, Okuma Y, Uchiyama T, et al. The prevalence, course and clinical correlates of migraine in Parkinson's disease: A multicentre case-controlled study. Cephalalgia. 2018;38:1535-44. doi: 10.1177/0333102417739302</mixed-citation></citation-alternatives></ref><ref id="cit14"><label>14</label><citation-alternatives><mixed-citation xml:lang="ru">Sampaio Rocha-Filho PA, Leite Souza-Lima CF. Parkinson's disease and headaches: A cross-sectional study. Headache. 2020;60:967-73. doi: 10.1111/head.13815</mixed-citation><mixed-citation xml:lang="en">Sampaio Rocha-Filho PA, Leite Souza-Lima CF. Parkinson's disease and headaches: A cross-sectional study. Headache. 2020;60:967-73. doi: 10.1111/head.13815</mixed-citation></citation-alternatives></ref><ref id="cit15"><label>15</label><citation-alternatives><mixed-citation xml:lang="ru">Angelopoulou E, Papadopoulos AN,Spantideas N, Bougea A. Migraine, tensiontype headache and Parkinson's Disease: A systematic review and meta-analysis. Medicina. 2022;58:1684. doi: 10.3390/medicina58111684</mixed-citation><mixed-citation xml:lang="en">Angelopoulou E, Papadopoulos AN,Spantideas N, Bougea A. Migraine, tensiontype headache and Parkinson's Disease: A systematic review and meta-analysis. Medicina. 2022;58:1684. doi: 10.3390/medicina58111684</mixed-citation></citation-alternatives></ref><ref id="cit16"><label>16</label><citation-alternatives><mixed-citation xml:lang="ru">Залялова ЗА, Яковлева ЛА, Алтунбаев РА. Болевой синдром при болезни Паркинсона. Журнал неврологии и психиатрии им. С.С. Корсакова. 2011;111(3):79-81.</mixed-citation><mixed-citation xml:lang="en">Zalyalova ZA, Yakovleva LA, Altunbaev RA. Pain syndrome in Parkinson's disease. Zhurnal nevrologiii psikhiatrii imeni S.S. Korsakova = S.S. Korsakov Journal of Neurology and Psychiatry. 2011;111(3):79-81 (In Russ.)].</mixed-citation></citation-alternatives></ref><ref id="cit17"><label>17</label><citation-alternatives><mixed-citation xml:lang="ru">Scher AI, Ross GW, Sigurdsson S, et al. Midlife migraine and late-life parkinsonism: AGES-Reykjavik study. Neurology. 2014 Sep 30;83(14):1246-52. doi: 10.1212/WNL.0000000000000840. Epub 2014 Sep 17.</mixed-citation><mixed-citation xml:lang="en">Scher AI, Ross GW, Sigurdsson S, et al. Midlife migraine and late-life parkinsonism: AGES-Reykjavik study. Neurology. 2014 Sep 30;83(14):1246-52. doi: 10.1212/WNL.0000000000000840. Epub 2014 Sep 17.</mixed-citation></citation-alternatives></ref><ref id="cit18"><label>18</label><citation-alternatives><mixed-citation xml:lang="ru">Wang HI, Ho YC, Huang YP, Pan SL. Migraine is related to an increased risk of Parkinson's disease: A population-based, propensity score-matched, longitudinal followup study. Cephalalgia. 2016 Dec;36(14):131623. doi: 10.1177/0333102416630577. Epub 2016 Feb 6.</mixed-citation><mixed-citation xml:lang="en">Wang HI, Ho YC, Huang YP, Pan SL. Migraine is related to an increased risk of Parkinson's disease: A population-based, propensity score-matched, longitudinal followup study. Cephalalgia. 2016 Dec;36(14):131623. doi: 10.1177/0333102416630577. Epub 2016 Feb 6.</mixed-citation></citation-alternatives></ref><ref id="cit19"><label>19</label><citation-alternatives><mixed-citation xml:lang="ru">De Oliveira Vilaca C, Leite MA, de Souza JA, et al. The Behavior of Migraine in Patients with Parkinson's Disease. Neurol Int. 2015 Dec 21;7(3):6133. doi: 10.4081/ni.2015.6133</mixed-citation><mixed-citation xml:lang="en">De Oliveira Vilaca C, Leite MA, de Souza JA, et al. The Behavior of Migraine in Patients with Parkinson's Disease. Neurol Int. 2015 Dec 21;7(3):6133. doi: 10.4081/ni.2015.6133</mixed-citation></citation-alternatives></ref><ref id="cit20"><label>20</label><citation-alternatives><mixed-citation xml:lang="ru">Barbanti P, Fabbrini G, Vanacore N, et al.Dopamine and migraine: does Parkinson's disease modify migraine course? Cephalalgia. 2000 Oct;20(8):720-3. doi: 10.1111/j.1468-2982.2000.00123.x</mixed-citation><mixed-citation xml:lang="en">Barbanti P, Fabbrini G, Vanacore N, et al.Dopamine and migraine: does Parkinson's disease modify migraine course? Cephalalgia. 2000 Oct;20(8):720-3. doi: 10.1111/j.1468-2982.2000.00123.x</mixed-citation></citation-alternatives></ref><ref id="cit21"><label>21</label><citation-alternatives><mixed-citation xml:lang="ru">Jatale V, Tiwari A, Kumar M, et al.Migraine and Tension-type Headache in Parkinson's Disease and Progressive Supranuclear Palsy/Corticobasal Syndrome. Ann Indian Acad Neurol. 2023 SepOct;26(5):708-14. doi: 10.4103/aian.aian_604_23. Epub 2023 Sep 25.</mixed-citation><mixed-citation xml:lang="en">Jatale V, Tiwari A, Kumar M, et al.Migraine and Tension-type Headache in Parkinson's Disease and Progressive Supranuclear Palsy/Corticobasal Syndrome. Ann Indian Acad Neurol. 2023 SepOct;26(5):708-14. doi: 10.4103/aian.aian_604_23. Epub 2023 Sep 25.</mixed-citation></citation-alternatives></ref><ref id="cit22"><label>22</label><citation-alternatives><mixed-citation xml:lang="ru">Jurado-Coronel JC, Cabezas R, Avila Rodriguez MF, et al. Sex differences in Parkinson's disease: Features on clinical symptoms, treatment outcome, sexual hormones and genetics. Front Neuroendocrinol. 2018 Jul;50:18-30. doi: 10.1016/j.yfrne.2017.09.002. Epub 2017 Sep 30.</mixed-citation><mixed-citation xml:lang="en">Jurado-Coronel JC, Cabezas R, Avila Rodriguez MF, et al. Sex differences in Parkinson's disease: Features on clinical symptoms, treatment outcome, sexual hormones and genetics. Front Neuroendocrinol. 2018 Jul;50:18-30. doi: 10.1016/j.yfrne.2017.09.002. Epub 2017 Sep 30.</mixed-citation></citation-alternatives></ref><ref id="cit23"><label>23</label><citation-alternatives><mixed-citation xml:lang="ru">Liampas I, Mylonas KS, Brotis A, et al. Serum lipid abnormalities in migraine: A meta-analysis of observational studies. Headache. 2021 Jan;61(1):44-59. doi: 10.1111/head.14039. Epub 2021 Jan 4.</mixed-citation><mixed-citation xml:lang="en">Liampas I, Mylonas KS, Brotis A, et al. Serum lipid abnormalities in migraine: A meta-analysis of observational studies. Headache. 2021 Jan;61(1):44-59. doi: 10.1111/head.14039. Epub 2021 Jan 4.</mixed-citation></citation-alternatives></ref><ref id="cit24"><label>24</label><citation-alternatives><mixed-citation xml:lang="ru">Peroutka SJ, Wilhoit T, Jones K. Clinicalsusceptibility to migraine with aura is modified by dopamine D2 receptor (DRD2) NcoI alleles. Neurology. 1997 Jul;49(1):201-6. doi: 10.1212/wnl.49.1.201</mixed-citation><mixed-citation xml:lang="en">Peroutka SJ, Wilhoit T, Jones K. Clinicalsusceptibility to migraine with aura is modified by dopamine D2 receptor (DRD2) NcoI alleles. Neurology. 1997 Jul;49(1):201-6. doi: 10.1212/wnl.49.1.201</mixed-citation></citation-alternatives></ref><ref id="cit25"><label>25</label><citation-alternatives><mixed-citation xml:lang="ru">Emin Erdal M, Herken H, Yilmaz M,Bayazit YA. Significance of the catechol-Omethyltransferase gene polymorphism in migraine. Brain Res Mol Brain Res. 2001 Oct 19;94(1-2):193-6. doi: 10.1016/s0169328x(01)00219-4</mixed-citation><mixed-citation xml:lang="en">Emin Erdal M, Herken H, Yilmaz M,Bayazit YA. Significance of the catechol-Omethyltransferase gene polymorphism in migraine. Brain Res Mol Brain Res. 2001 Oct 19;94(1-2):193-6. doi: 10.1016/s0169328x(01)00219-4</mixed-citation></citation-alternatives></ref><ref id="cit26"><label>26</label><citation-alternatives><mixed-citation xml:lang="ru">Cevoli S, Mochi M, Scapoli C, et al. A genetic association study of dopamine metabolism-related genes and chronic headache with drug abuse. Eur J Neurol. 2006 Sep;13(9):1009-13. doi: 10.1111/j.1468-1331.2006.01415.x</mixed-citation><mixed-citation xml:lang="en">Cevoli S, Mochi M, Scapoli C, et al. A genetic association study of dopamine metabolism-related genes and chronic headache with drug abuse. Eur J Neurol. 2006 Sep;13(9):1009-13. doi: 10.1111/j.1468-1331.2006.01415.x</mixed-citation></citation-alternatives></ref><ref id="cit27"><label>27</label><citation-alternatives><mixed-citation xml:lang="ru">Indo T, Naito A, Sobue I. Clinical characteristics of headache in Parkinson's disease. Headache. 1983 Sep;23(5):211-2. doi: 10.1111/j.1526-4610.1983.hed2305211.x</mixed-citation><mixed-citation xml:lang="en">Indo T, Naito A, Sobue I. Clinical characteristics of headache in Parkinson's disease. Headache. 1983 Sep;23(5):211-2. doi: 10.1111/j.1526-4610.1983.hed2305211.x</mixed-citation></citation-alternatives></ref><ref id="cit28"><label>28</label><citation-alternatives><mixed-citation xml:lang="ru">Meco G, Frascarelli M, Pratesi L, et al. Headache in Parkinson's disease. Headache. 1988 Feb;28(1):26-9. doi: 10.1111/j.13652524.1988.hed2801026.x</mixed-citation><mixed-citation xml:lang="en">Meco G, Frascarelli M, Pratesi L, et al. Headache in Parkinson's disease. Headache. 1988 Feb;28(1):26-9. doi: 10.1111/j.13652524.1988.hed2801026.x</mixed-citation></citation-alternatives></ref><ref id="cit29"><label>29</label><citation-alternatives><mixed-citation xml:lang="ru">Van Hilten JJ. The migraine-dopamine link: do migraine and Parkinson's disease coexist? Clin Neurol Neurosurg. 1992;94 Suppl:S168-70. doi: 10.1016/0303-8467(92)90060-g</mixed-citation><mixed-citation xml:lang="en">Van Hilten JJ. The migraine-dopamine link: do migraine and Parkinson's disease coexist? Clin Neurol Neurosurg. 1992;94 Suppl:S168-70. doi: 10.1016/0303-8467(92)90060-g</mixed-citation></citation-alternatives></ref><ref id="cit30"><label>30</label><citation-alternatives><mixed-citation xml:lang="ru">Cubo E, Kompoliti K, Leurgans SE,Raman R. Dopaminergic hypersensitivity in patients with Parkinson disease and migraine. Clin Neuropharmacol. 2004 Jan-Feb;27(1):30-2. doi: 10.1097/00002826-200401000-00009</mixed-citation><mixed-citation xml:lang="en">Cubo E, Kompoliti K, Leurgans SE,Raman R. Dopaminergic hypersensitivity in patients with Parkinson disease and migraine. Clin Neuropharmacol. 2004 Jan-Feb;27(1):30-2. doi: 10.1097/00002826-200401000-00009</mixed-citation></citation-alternatives></ref><ref id="cit31"><label>31</label><citation-alternatives><mixed-citation xml:lang="ru">Парфенов ВА, Пожидаев КА. Хроническая мигрень в пожилом возрасте. Клиническая геронтология. 2019;25(5-6):47-51. doi: 10.26347/1607-2499201905-06047-0151</mixed-citation><mixed-citation xml:lang="en">Парфенов ВА, Пожидаев КА. Хроническая мигрень в пожилом возрасте. Клиническая геронтология. 2019;25(5-6):47-51. doi: 10.26347/1607-2499201905-06047-0151 [Parfenov VA, Pozhidaev K.A. Chronic migraine in the elderly. Klinicheskaya gerontologiya = Clinical Gerontology. 2019;25(5-6):4751. doi: 10.26347/1607-2499201905-060470151 (In Russ.)].</mixed-citation></citation-alternatives></ref><ref id="cit32"><label>32</label><citation-alternatives><mixed-citation xml:lang="ru">Charbit AR, Akerman S, Goadsby PJ.Dopamine: what's new in migraine? Curr Opin Neurol. 2010;23:275-81. doi: 10.1097/WCO.0b013e3283378d5c</mixed-citation><mixed-citation xml:lang="en">Charbit AR, Akerman S, Goadsby PJ.Dopamine: what's new in migraine? Curr Opin Neurol. 2010;23:275-81. doi: 10.1097/WCO.0b013e3283378d5c</mixed-citation></citation-alternatives></ref><ref id="cit33"><label>33</label><citation-alternatives><mixed-citation xml:lang="ru">Akerman S, Goadsby PJ. Dopamine and migraine: biology and clinical implications. Cephalalgia. 2007 Nov;27(11):1308-14. doi: 10.1111/j.1468-2982.2007.01478.x</mixed-citation><mixed-citation xml:lang="en">Akerman S, Goadsby PJ. Dopamine and migraine: biology and clinical implications. Cephalalgia. 2007 Nov;27(11):1308-14. doi: 10.1111/j.1468-2982.2007.01478.x</mixed-citation></citation-alternatives></ref><ref id="cit34"><label>34</label><citation-alternatives><mixed-citation xml:lang="ru">Page MJ, McKenzie JE, Bossuyt PM, et al.The PRISMA 2020 statement: an updated guideline for reporting systematic reviews. BMJ. 2021 Mar 29;372:n71. doi: 10.1136/bmj.n71</mixed-citation><mixed-citation xml:lang="en">Page MJ, McKenzie JE, Bossuyt PM, et al.The PRISMA 2020 statement: an updated guideline for reporting systematic reviews. BMJ. 2021 Mar 29;372:n71. doi: 10.1136/bmj.n71</mixed-citation></citation-alternatives></ref><ref id="cit35"><label>35</label><citation-alternatives><mixed-citation xml:lang="ru">Lin YK, Tsai CL, Lin GY, et al.Pathophysiology of Chronic Migraine: Insights from Recent Neuroimaging Research. Curr Pain Headache Rep. 2022 Nov;26(11):843-54. doi: 10.1007/s11916-022-01087-x. Epub 2022 Oct 7.</mixed-citation><mixed-citation xml:lang="en">Lin YK, Tsai CL, Lin GY, et al.Pathophysiology of Chronic Migraine: Insights from Recent Neuroimaging Research. Curr Pain Headache Rep. 2022 Nov;26(11):843-54. doi: 10.1007/s11916-022-01087-x. Epub 2022 Oct 7.</mixed-citation></citation-alternatives></ref><ref id="cit36"><label>36</label><citation-alternatives><mixed-citation xml:lang="ru">Niddam DM, Lai KL, Tsai SY, et al.Neurochemical changes in the medial wall of the brain in chronic migraine. Brain. 2018 Feb 1;141(2):377-90. doi: 10.1093/brain/awx331</mixed-citation><mixed-citation xml:lang="en">Niddam DM, Lai KL, Tsai SY, et al.Neurochemical changes in the medial wall of the brain in chronic migraine. Brain. 2018 Feb 1;141(2):377-90. doi: 10.1093/brain/awx331</mixed-citation></citation-alternatives></ref><ref id="cit37"><label>37</label><citation-alternatives><mixed-citation xml:lang="ru">Albrecht DS, Mainero C, Ichijo E, et al.Imaging of neuroinflammation in migraine with aura: a [11C]PBR28 PET/MRI study. Neurology. 2019;92:e2038-e2050. doi: 10.1212/WNL.0000000000007371</mixed-citation><mixed-citation xml:lang="en">Albrecht DS, Mainero C, Ichijo E, et al.Imaging of neuroinflammation in migraine with aura: a [11C]PBR28 PET/MRI study. Neurology. 2019;92:e2038-e2050. doi: 10.1212/WNL.0000000000007371</mixed-citation></citation-alternatives></ref><ref id="cit38"><label>38</label><citation-alternatives><mixed-citation xml:lang="ru">Begg CB, Mazumdar M. Operating characteristics of a rank correlation test for publication bias. Biometrics. 1994 Dec;50(4):1088-101.</mixed-citation><mixed-citation xml:lang="en">Begg CB, Mazumdar M. Operating characteristics of a rank correlation test for publication bias. Biometrics. 1994 Dec;50(4):1088-101.</mixed-citation></citation-alternatives></ref><ref id="cit39"><label>39</label><citation-alternatives><mixed-citation xml:lang="ru">Катунина ЕА, Залялова ЗА, Похабов ДВи др. Болезнь Паркинсона. Фокус на ранние стадии. Неврология, нейропсихиатрия, психосоматика. 2023;15(3):95-103. doi: 10.14412/2074-2711-2023-3-95-103</mixed-citation><mixed-citation xml:lang="en">Katunina EA, Zalyalova ZA, Pokhabov DV, et al. Parkinson's disease. Focus on early stages. Nevrologiya, neiropsikhiatriya, psikhosomatika = Neurology, Neuropsychiatry, Psychosomatics. 2023;15(3):95-103. doi: 10.14412/2074-27112023-3-95-103 (In Russ.)].</mixed-citation></citation-alternatives></ref><ref id="cit40"><label>40</label><citation-alternatives><mixed-citation xml:lang="ru">Antonini A, Tinazzi M, Abbruzzese G, et al.Pain in Parkinson's disease: facts and uncertainties. Eur J Neurol. 2018 Jul;25(7):917-e69. doi: 10.1111/ene.13624. Epub 2018 Apr 18.</mixed-citation><mixed-citation xml:lang="en">Antonini A, Tinazzi M, Abbruzzese G, et al.Pain in Parkinson's disease: facts and uncertainties. Eur J Neurol. 2018 Jul;25(7):917-e69. doi: 10.1111/ene.13624. Epub 2018 Apr 18.</mixed-citation></citation-alternatives></ref><ref id="cit41"><label>41</label><citation-alternatives><mixed-citation xml:lang="ru">Fox SH, Chuang R, Brotchie JM.Serotonin and Parkinson's disease: On movement, mood, and madness. Mov Disord. 2009 Jul 15;24(9):1255-66. doi: 10.1002/mds.22473</mixed-citation><mixed-citation xml:lang="en">Fox SH, Chuang R, Brotchie JM.Serotonin and Parkinson's disease: On movement, mood, and madness. Mov Disord. 2009 Jul 15;24(9):1255-66. doi: 10.1002/mds.22473</mixed-citation></citation-alternatives></ref><ref id="cit42"><label>42</label><citation-alternatives><mixed-citation xml:lang="ru">Braak H, Ghebremedhin E, Rüb U, et al. Stages in the development of Parkinson's disease-related pathology. Cell Tissue Res. 2004 Oct;318(1):121-34. doi: 10.1007/s00441-0040956-9. Epub 2004 Aug 24.</mixed-citation><mixed-citation xml:lang="en">Braak H, Ghebremedhin E, Rüb U, et al. Stages in the development of Parkinson's disease-related pathology. Cell Tissue Res. 2004 Oct;318(1):121-34. doi: 10.1007/s00441-0040956-9. Epub 2004 Aug 24.</mixed-citation></citation-alternatives></ref><ref id="cit43"><label>43</label><citation-alternatives><mixed-citation xml:lang="ru">Mendlin A, Martin FJ, Jacobs BL.Dopaminergic input is required for increases in serotonin output produced by behavioral activation: an in vivo microdialysis study in rat forebrain. Neuroscience. 1999;93(3):897-905. doi: 10.1016/s0306-4522(99)00213-4</mixed-citation><mixed-citation xml:lang="en">Mendlin A, Martin FJ, Jacobs BL.Dopaminergic input is required for increases in serotonin output produced by behavioral activation: an in vivo microdialysis study in rat forebrain. Neuroscience. 1999;93(3):897-905. doi: 10.1016/s0306-4522(99)00213-4</mixed-citation></citation-alternatives></ref><ref id="cit44"><label>44</label><citation-alternatives><mixed-citation xml:lang="ru">Ashina S, Bendtsen L, Ashina M.Pathophysiology of tension-type headache. Curr Pain Headache Rep. 2005 Dec;9(6):415-22. doi: 10.1007/s11916-005-0021-8</mixed-citation><mixed-citation xml:lang="en">Ashina S, Bendtsen L, Ashina M.Pathophysiology of tension-type headache. Curr Pain Headache Rep. 2005 Dec;9(6):415-22. doi: 10.1007/s11916-005-0021-8</mixed-citation></citation-alternatives></ref><ref id="cit45"><label>45</label><citation-alternatives><mixed-citation xml:lang="ru">Aggarwal M, Puri V, Puri S. Serotonin and CGRP in migraine. Ann Neurosci. 2012 Apr;19(2):88-94. doi: 10.5214/ans.0972.7531.12190210</mixed-citation><mixed-citation xml:lang="en">Aggarwal M, Puri V, Puri S. Serotonin and CGRP in migraine. Ann Neurosci. 2012 Apr;19(2):88-94. doi: 10.5214/ans.0972.7531.12190210</mixed-citation></citation-alternatives></ref><ref id="cit46"><label>46</label><citation-alternatives><mixed-citation xml:lang="ru">Saengjaroentham C, Supornsilpchai W, Ji-Au W, et al. Serotonin depletion can enhance the cerebrovascular responses induced by cortical spreading depression via the nitric oxide pathway. Int J Neurosci. 2015 Feb;125(2):130-9. doi: 10.3109/00207454.2014.908876. Epub 2014 May 19.</mixed-citation><mixed-citation xml:lang="en">Saengjaroentham C, Supornsilpchai W, Ji-Au W, et al. Serotonin depletion can enhance the cerebrovascular responses induced by cortical spreading depression via the nitric oxide pathway. Int J Neurosci. 2015 Feb;125(2):130-9. doi: 10.3109/00207454.2014.908876. Epub 2014 May 19.</mixed-citation></citation-alternatives></ref><ref id="cit47"><label>47</label><citation-alternatives><mixed-citation xml:lang="ru">Dusek P, Jankovic J, Le W. Iron dysregulation in movement disorders. Neurobiol Dis. 2012 Apr;46(1):1-18. doi: 10.1016/j.nbd.2011.12.054. Epub 2012 Jan 12.</mixed-citation><mixed-citation xml:lang="en">Dusek P, Jankovic J, Le W. Iron dysregulation in movement disorders. Neurobiol Dis. 2012 Apr;46(1):1-18. doi: 10.1016/j.nbd.2011.12.054. Epub 2012 Jan 12.</mixed-citation></citation-alternatives></ref><ref id="cit48"><label>48</label><citation-alternatives><mixed-citation xml:lang="ru">Kruit MC, Launer LJ, Overbosch J, et al.Iron accumulation in deep brain nuclei in migraine: a population-based magnetic resonance imaging study. Cephalalgia. 2009 Mar;29(3):351-9. doi: 10.1111/j.14682982.2008.01723.x. Epub 2008 Nov 19.</mixed-citation><mixed-citation xml:lang="en">Kruit MC, Launer LJ, Overbosch J, et al.Iron accumulation in deep brain nuclei in migraine: a population-based magnetic resonance imaging study. Cephalalgia. 2009 Mar;29(3):351-9. doi: 10.1111/j.14682982.2008.01723.x. Epub 2008 Nov 19.</mixed-citation></citation-alternatives></ref><ref id="cit49"><label>49</label><citation-alternatives><mixed-citation xml:lang="ru">Chen Z, Zhao H, Chen X, et al. The increased iron deposition of the gray matter over the whole brain in chronic migraine: An exploratory quantitative susceptibility mapping study. Mol Pain. 2022 JanDec;18:17448069221074987. doi: 10.1177/17448069221074987</mixed-citation><mixed-citation xml:lang="en">Chen Z, Zhao H, Chen X, et al. The increased iron deposition of the gray matter over the whole brain in chronic migraine: An exploratory quantitative susceptibility mapping study. Mol Pain. 2022 JanDec;18:17448069221074987. doi: 10.1177/17448069221074987</mixed-citation></citation-alternatives></ref><ref id="cit50"><label>50</label><citation-alternatives><mixed-citation xml:lang="ru">Edvinsson L. Role of CGRP in migraine.Handb Exp Pharmacol. 2019;255:121-30. doi: 10.1007/164_2018_201</mixed-citation><mixed-citation xml:lang="en">Edvinsson L. Role of CGRP in migraine.Handb Exp Pharmacol. 2019;255:121-30. doi: 10.1007/164_2018_201</mixed-citation></citation-alternatives></ref><ref id="cit51"><label>51</label><citation-alternatives><mixed-citation xml:lang="ru">Raffaelli B, Storch E, Overeem LH, et al.Sex Hormones and Calcitonin Gene-Related Peptide in Women With Migraine: A Cross-sectional, Matched Cohort Study. Neurology. 2023 Apr 25;100(17):e1825-e1835. doi: 10.1212/WNL.0000000000207114. Epub 2023 Feb 22.</mixed-citation><mixed-citation xml:lang="en">Raffaelli B, Storch E, Overeem LH, et al.Sex Hormones and Calcitonin Gene-Related Peptide in Women With Migraine: A Cross-sectional, Matched Cohort Study. Neurology. 2023 Apr 25;100(17):e1825-e1835. doi: 10.1212/WNL.0000000000207114. Epub 2023 Feb 22.</mixed-citation></citation-alternatives></ref><ref id="cit52"><label>52</label><citation-alternatives><mixed-citation xml:lang="ru">Labastida-Ramirez A, Rubio-Beltran E,Villalon CM, MaassenVanDenBrink A. Gender aspects of CGRP in migraine. Cephalalgia. 2019 Mar;39(3):435-44. doi: 10.1177/0333102417739584. Epub 2017 Oct 30.</mixed-citation><mixed-citation xml:lang="en">Labastida-Ramirez A, Rubio-Beltran E,Villalon CM, MaassenVanDenBrink A. Gender aspects of CGRP in migraine. Cephalalgia. 2019 Mar;39(3):435-44. doi: 10.1177/0333102417739584. Epub 2017 Oct 30.</mixed-citation></citation-alternatives></ref><ref id="cit53"><label>53</label><citation-alternatives><mixed-citation xml:lang="ru">Thornton E, Vink R. Substance P and itstachykinin NK1 receptor: a novel neuroprotective target for Parkinson's disease. Neural Regen Res. 2015 Sep;10(9):1403-5. doi: 10.4103/16735374.165505</mixed-citation><mixed-citation xml:lang="en">Thornton E, Vink R. Substance P and itstachykinin NK1 receptor: a novel neuroprotective target for Parkinson's disease. Neural Regen Res. 2015 Sep;10(9):1403-5. doi: 10.4103/16735374.165505</mixed-citation></citation-alternatives></ref><ref id="cit54"><label>54</label><citation-alternatives><mixed-citation xml:lang="ru">Gimeno-Ferrer F, Eitner A, Bauer R, et al.From spreading depolarization to epilepsy with neuroinflammation: The role of CGRP in cortex. Exp Neurol. 2022 Oct;356:114152. doi: 10.1016/j.expneurol.2022.114152. Epub 2022 Jun 26.</mixed-citation><mixed-citation xml:lang="en">Gimeno-Ferrer F, Eitner A, Bauer R, et al.From spreading depolarization to epilepsy with neuroinflammation: The role of CGRP in cortex. Exp Neurol. 2022 Oct;356:114152. doi: 10.1016/j.expneurol.2022.114152. Epub 2022 Jun 26.</mixed-citation></citation-alternatives></ref><ref id="cit55"><label>55</label><citation-alternatives><mixed-citation xml:lang="ru">Di Angelantonio S, Giniatullin R, Costa V,et al. Modulation of neuronal nicotinic receptor function by the neuropeptides CGRP and substance P on autonomic nerve cells. Br J Pharmacol. 2003 Jul;139(6):1061-73. doi: 10.1038/sj.bjp.0705337</mixed-citation><mixed-citation xml:lang="en">Di Angelantonio S, Giniatullin R, Costa V,et al. Modulation of neuronal nicotinic receptor function by the neuropeptides CGRP and substance P on autonomic nerve cells. Br J Pharmacol. 2003 Jul;139(6):1061-73. doi: 10.1038/sj.bjp.0705337</mixed-citation></citation-alternatives></ref><ref id="cit56"><label>56</label><citation-alternatives><mixed-citation xml:lang="ru">Svenningsson P, Palhagen S, Mathe AA. Neuropeptide Y and Calcitonin Gene-Related Peptide in Cerebrospinal Fluid in Parkinson's Disease with Comorbid Depression versus Patients with Major Depressive Disorder. Front Psychiatry. 2017 Jun 12;8:102. doi: 10.3389/fpsyt.2017.00102</mixed-citation><mixed-citation xml:lang="en">Svenningsson P, Palhagen S, Mathe AA. Neuropeptide Y and Calcitonin Gene-Related Peptide in Cerebrospinal Fluid in Parkinson's Disease with Comorbid Depression versus Patients with Major Depressive Disorder. Front Psychiatry. 2017 Jun 12;8:102. doi: 10.3389/fpsyt.2017.00102</mixed-citation></citation-alternatives></ref><ref id="cit57"><label>57</label><citation-alternatives><mixed-citation xml:lang="ru">Hamed SA. The vascular risk associationswith migraine: relation to migraine susceptibility and progression. Atherosclerosis. 2009 Jul;205(1):15-22. doi: 10.1016/j.atherosclerosis.2008.10.016. Epub 2008 Nov 1.</mixed-citation><mixed-citation xml:lang="en">Hamed SA. The vascular risk associationswith migraine: relation to migraine susceptibility and progression. Atherosclerosis. 2009 Jul;205(1):15-22. doi: 10.1016/j.atherosclerosis.2008.10.016. Epub 2008 Nov 1.</mixed-citation></citation-alternatives></ref><ref id="cit58"><label>58</label><citation-alternatives><mixed-citation xml:lang="ru">Красников АВ, Шведков ВВ, Шабалина АА, Костырева МВ. Диагностика дислипидемии при эпизодической мигрени. Журнал неврологии и психиатрии им. С.С. Корсакова. 2019;119(5):17-8. doi: 10.17116/pain2021190325</mixed-citation><mixed-citation xml:lang="en">Krasnikov AV, Shvedkov VV, Shabalina AA, Kostyreva MV. Diagnostics of dyslipidemia in episodic migraine. Zhurnal nevrologiii psikhiatrii imeni S.S. Korsakova = S.S. Korsakov Journal of Neurology and Psychiatry. 2019;119(5):17-8. doi: 10.17116/pain2021190325 (In Russ.)].</mixed-citation></citation-alternatives></ref><ref id="cit59"><label>59</label><citation-alternatives><mixed-citation xml:lang="ru">Hu G, Antikainen R, Jousilahti P, et al.Total cholesterol and the risk of Parkinson disease. Neurology. 2008 May 20;70(21):1972-9. doi: 10.1212/01.wnl.0000312511.62699.a8. Epub 2008 Apr 9.</mixed-citation><mixed-citation xml:lang="en">Hu G, Antikainen R, Jousilahti P, et al.Total cholesterol and the risk of Parkinson disease. Neurology. 2008 May 20;70(21):1972-9. doi: 10.1212/01.wnl.0000312511.62699.a8. Epub 2008 Apr 9.</mixed-citation></citation-alternatives></ref><ref id="cit60"><label>60</label><citation-alternatives><mixed-citation xml:lang="ru">Nam GE, Kim SM, Han K, et al.Metabolic syndrome and risk of Parkinson disease: a nationwide cohort study. PLoS Med. 2018;15:e1002640. doi: 10.1371/journal.pmed.1002640</mixed-citation><mixed-citation xml:lang="en">Nam GE, Kim SM, Han K, et al.Metabolic syndrome and risk of Parkinson disease: a nationwide cohort study. PLoS Med. 2018;15:e1002640. doi: 10.1371/journal.pmed.1002640</mixed-citation></citation-alternatives></ref><ref id="cit61"><label>61</label><citation-alternatives><mixed-citation xml:lang="ru">Chen H, Zhang SM, Hernaan MA, et al. Dietary intakes of fat and risk of Parkinson's disease. Am J Epidemiol. 2003;157:1007-14. doi: 10.1093/aje/kwg073</mixed-citation><mixed-citation xml:lang="en">Chen H, Zhang SM, Hernaan MA, et al. Dietary intakes of fat and risk of Parkinson's disease. Am J Epidemiol. 2003;157:1007-14. doi: 10.1093/aje/kwg073</mixed-citation></citation-alternatives></ref></ref-list><fn-group><fn fn-type="conflict"><p>The authors declare that there are no conflicts of interest present.</p></fn></fn-group></back></article>
